Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Key Points

• Deutsche Bank Aktiengesellschaft raised its price target for Edwards Lifesciences from $85.00 to $94.00, indicating a potential 24.21% upside from the last closing price.
• Edwards Lifesciences reported an earnings per share (EPS) of $0.67 for the last quarter, exceeding expectations of $0.62, with revenues of $1.53 billion versus the forecast of $1.49 billion.
• Institutional investors and hedge funds own 79.46% of Edwards Lifesciences, highlighting significant institutional interest in the stock.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price objective boosted by Deutsche Bank Aktiengesellschaft from $85.00 to $94.00 in a report released on Friday,Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. Deutsche Bank Aktiengesellschaft's price target indicates a potential upside of 24.21% from the company's previous close.

Several other equities analysts have also weighed in on EW. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Mizuho increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Citigroup reissued a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $81.62.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $75.68 on Friday. The stock's fifty day moving average is $76.54 and its 200-day moving average is $73.52. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The stock has a market capitalization of $44.39 billion, a PE ratio of 10.81, a PEG ratio of 3.86 and a beta of 1.11. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $78.90.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share. Equities research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total transaction of $837,000.00. Following the completion of the transaction, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,848 shares of company stock worth $2,314,488 in the last three months. Insiders own 1.29% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $610,895,000. Nuveen LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $330,881,000. Jennison Associates LLC boosted its position in shares of Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Edwards Lifesciences by 55.7% during the fourth quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock valued at $430,367,000 after buying an additional 2,079,642 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.